Potential for all-trans retinoic acid [tretinoin] to enhance interferon-α treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma

Cancer Biology and Therapy

Volumn 7, Issue 10, 2008, Pages 1515-1519

  Kast, Richard E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Chronic myelogenous leukemia; Hepatitis C; Interferon alpha; Melanoma; Myeloma; Retinoic acid; Tretinoin

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; ALPHA2B INTERFERON; ALPHAN3 INTERFERON; BEXAROTENE; CONSENSUS INTERFERON; DOUBLE STRANDED RNA; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 10; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2B INTERFERON; RETINOIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; RETINOID DERIVATIVE; RIBAVIRIN; RIBONUCLEASE L;

ACNE; ACNE VULGARIS; ADAPTIVE IMMUNITY; ADD ON THERAPY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; BURKITT LYMPHOMA; CELL KILLING; CHRONIC MYELOID LEUKEMIA; CONDYLOMA ACUMINATUM; CUTANEOUS T CELL LYMPHOMA; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; EPSTEIN BARR VIRUS; GENE AMPLIFICATION; HAIRY CELL LEUKEMIA; HEPATITIS C; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTIOUS MONONUCLEOSIS; KAPOSI SARCOMA; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; LYMPHOMA; MELANOMA; MITOSIS; MOLLUSCUM CONTAGIOSUM; MYELOMA; NATURAL KILLER CELL; PROMYELOCYTIC LEUKEMIA; PSORIASIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA CLEAVAGE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; VIRUS INFECTION; VIRUS REPLICATION; WRINKLE;

EID: 54349102283     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.10.6573     Document Type: Review

References (48)

1. Böcher WO, Wallasch C, Höhler T, Galle PR. All-trans retinoic acid for treatment of chronic hepatitis C. Liver Int 2008; 28:347-54.
2. Hehlmann R, Hochhaus A, Baccarani M, European Leukemia Net. Chronic myeloid leukaemia. Lancet 2007; 370:342-50.
3. Kujawski LA, Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia. Cytokine Growth Factor Rev 2007; 18:459-71.
4. Eggermont AM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol 2007; 34:509-15.
5. Shah GD, Chapman PB. Adjuvant therapy of melanoma. Cancer J 2007; 13:217-22.
6. Schaar CG, Kluin-Nelemans HC, Te Marvelde C, le Cessie S, Breed WP, Fibbe WE, van Deijk WA, Fickers MM, Roozendaal KJ, Wijermans PW. Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol 2005; 16:634-9.
7. Chiou TJ, Wang TH, Chao TY, Lin SF, Tang JL, Chen TY, Chang MC, Hsueh EJ, Chen PM. Randomized Phase II trial of thalidomide alone versus thalidomide plus interferon alpha in patients with refractory multiple myeloma. Cancer Invest 2007; 25:140-7.
8. Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007; 12:1404-15.
9. McDermott DF, Rini BI. Immunotherapy for metastatic renal cell carcinoma. BJU Int 2007; 99:1282-8.
10. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007; 282:20053-7.
11. Ferrantini M, Capone I, Belardelli F. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 2007; 89:884-93.
12. Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J. Distinct functions of IRF-3 and IRF-7 in IFNalpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol 2006; 72:1469-76.
13. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR, Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 2007; 6:793-810.
14. de Lera AR, Bourguet W, Altucci L, Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat Rev Drug Discov 2007; 6:811-20.
15. Su ZZ, Sarkar D, Emdad L, Barral PM, Fisher PB. Central role of interferon regulatory factor-1 (IRF-1) in controlling retinoic acid inducible gene-I (RIG-I) expression. J Cell Physiol 2007; 213:502-10.
16. Thompson AJ, Locarnini SA. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Immunol Cell Biol 2007; 85:435-45.
17. Chi H, Flavell RA. Innate recognition of non-self nucleic acids. Genome Biol 2008; 9:211.
18. Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 2006; 441:101-5.
19. Huang SL, Shyu RY, Yeh MY, Jiang SY. Cloning and characterization of a novel retinoid-inducible gene 1 (RIG1) deriving from human gastric cancer cells. Mol Cell Endocrinol 2000; 159:15-24.
20. Vitour D, Meurs EF. Regulation of interferon production by RIG-I and LGP2: a lesson in self-control. Sci STKE 2007; 2007:20.
21. Zhang C, Duvic M. Treatment of cutaneous T-cell lymphoma with retinoids. Dermatol Ther 2006; 19:264-71.
22. Gee P, Chua PK, Gevorkyan J, Klumpp K, Najera I, Swinney DC, Deval J. Essential Role of the N-terminal Domain in the Regulation of RIG-I ATPase Activity. J Biol Chem 2008; 283:9488-96.
23. Takeuchi O, Akira S. MDA5/RIG-I and virus recognition. Curr Opin Immunol 2008; 20:17-22.
24. Bougie I, Bisaillon M. The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem 2004; 279:22124-30.
25. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437:1167-72.
26. Foy E, Li K, Sumpter R Jr, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling.Proc Natl Acad Sci USA 2005; 102:2986-91.
27. Hiscott J, Lin R, Nakhaei P, Paz S. MasterCARD: a priceless link to innate immunity. Trends Mol Med 2006; 12:53-6.
28. Kumar H, Kawai T, Kato H, et al. Essential role of IPS-1 in innate immune responses against RNA viruses. J Exp Med 2006; 203:1795-803.
29. Kawai T, Takahashi K, Sato S, et al. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol 2005; 6:981-8.
30. Gack MU, Shin YC, Joo CH, et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature 2007; 446:916-920.
31. Paz S, Sun Q, Nakhaei P, Romieu-Mourez R, Goubau D, Julkunen I, Lin R, Hiscott J. Induction of IRF-3 and IRF-7 phosphorylation following activation of the RIG-I pathway. Cell Mol Biol (Noisy-le-grand) 2006; 52:17-28.
32. Kishore N, Huynh QK, Mathialagan S, et al. IKK-i and TBK-1 are enzymatically distinct from the homologous enzyme IKK-2: comparative analysis of recombinant human IKK-i, TBK-1 and IKK-2. J Biol Chem 2002; 277:13840-7.
33. Yoneyama M, Suhara W, Fujita T. Control of IRF-3 activation by phosphorylation. J Interferon Cytokine Res 2002; 22:73-6.
34. Yoneyama M, Suhara W, Fukuhara Y, Fukuda M, Nishida E, Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. EMBO J 1998; 17:1087-95.
35. Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM, Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003; 4:491-6.
36. Häcker H, Karin M. Regulation and function of IKK and IKK-related kinases. Sci STKE 2006; 2006:13.
37. Marié I, Durbin JE, Levy DE. Differential viral induction of distinct interferon-alpha genes by positive feedback through interferon regulatory factor-7. EMBO J 1998; 17:6660-9.
38. Sato M, Hata N, Asagiri M, Nakaya T, Taniguchi T, Tanaka N. Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett 1998; 441:106-10.
39. Servant MJ, Tenoever B, Lin R. Overlapping and distinct mechanisms regulating IRF-3 and IRF-7 function. J Interferon Cytokine Res 2002; 22:49-58.
40. Lin R, Lacoste J, Nakhaei P, et al. Dissociation of a MAVS/IPS-1/VISA/Cardif-IKKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage. J Virol 2006; 80:6072-83.
41. Sillanpää M, Kaukinen P, Melén K, Julkunen I. Hepatitis C virus proteins interfere with the activation of chemokine genepromoters and downregulate chemokine gene expression. J Gen Virol 2008; 89:432-43.
42. Loo YM, Owen DM, Li K, et al. Viral and therapeutic control of IFNbeta promoter stimulator 1 during hepatitis C virus infection.Proc Natl Acad Sci USA 2006; 103:6001-6.
43. Malathi K, Dong B, Gale M Jr, Silverman RH. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature 2007; 448:816-9.
44. Kaukinen P, Sillanpää M, Kotenko S, Lin R, Hiscott J, Melén K, Julkunen I. Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expression. Virol J 2006; 3:66.
45. Samanta M, Iwakiri D, Kanda T, Imaizumi T, Takada K. EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J 2006; 25:4207-14.
46. Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Investig Drugs 2008; 17:437-43.
47. Boorjian SA, Milowsky MI, Kaplan J, et al. Phase 1/2 clinical trial of interferon alpha2b and weekly liposome-encapsulated all-trans retinoic acid in patients with advanced renal cell carcinoma. J Immunother 2007; 30:655-62.
48. Regazzi MB, Russo D, Iacona I, et al. Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off. Clin Drug Investig 1998; 16:25-33.